A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.
Sara M. Tolaney
No relevant relationships to disclose
Hao Guo
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Katherine Larrabee
No relevant relationships to disclose
Jane E. Brock
No relevant relationships to disclose
Nikhil Wagle
No relevant relationships to disclose
Eliezer Mendel Van Allen
No relevant relationships to disclose
Cloud Paweletz
No relevant relationships to disclose
Elena Ivanova
No relevant relationships to disclose
Pasi A. Janne
No relevant relationships to disclose
Beth Overmoyer
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Geoffrey Shapiro
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Ian E. Krop
No relevant relationships to disclose